Dr. Ogugua N. Obi, Director of the Sarcoidosis Center of Excellence at ECU, presented the latest update on XTMAB-16 in …

The story of XTMAB-16 is one of trust, collaboration, expertise and tenacity combining to create an outcome that matched the …

Jul 2, 2026 · A Seamless, Adaptive Multiple-Ascending-Dose and Efficacy Study of XTMAB-16 in Patients with Pulmonary …

XTMAB-16 is a chimeric human-murine IgG1k anti-TNFa monoclonal antibody with a molecular weight of ~149 kDa being developed …

May 1, 2025 · Results Part A will evaluate the safety and tolerability of multiple-ascending doses of XTMAB-16 in 32 participants with …

Dec 13, 2023 · Evidence of treatment-related AEs requiring treatment discontinuation per XTMAB-16-201 protocol observed in …

Characterization studies were performed on XTMAB-16 drug substance batches produced in the commercial scale. Results include …

The aim of this study is to examine how well XTAMB-16 helps improve sarcoidosis by measuring the participants’ use of oral …

Mar 25, 2025 · This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion …

May 16, 2026 · XTMAB-16 is a chimeric anti-tumor necrosis factor alpha (TNFα) antibody, distinct from other anti-TNF antibodies …